Opzelura generic
Opzelura, an anti-vitiligo and atopic dermatitis drug, is owned by Incyte Corp. The active ingredient of this medication is ruxolitinib phosphate. First authorized for market use on 21 September 2021, Opzelura has a total of 28 patents, none of which have expired yet. It is available in cream and topical dosage forms.
When will Opzelura generic be available?
The generic versions of Opzelura, due to its robust patent profile, are not expected to hit the market until after 05 May, 2041. This is primarily due to the expiry of its last patent on that date. Thus we can expect Opzelura generic drugs post this time frame.
Opzelura uses
Opzelura is widely used in the topical treatment of non-segmental vitiligo across adult and pediatric patients aged 12 and above. It can be used in the absence of phototherapy and is particularly effective when vitiligo affects at least one of the lower extremities, trunk, and feet of the patient. The primary contribution of its active ingredient, ruxolitinib phosphate, towards its effectiveness lies in its use as a Janus kinase inhibitor. Additionally, it's also used for topical short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients if their disease isn't adequately controlled with other topical prescription therapies, or when those therapies are not advisable.
Opzelura patent expiration
Opzelura's patent portfolio is diverse, consisting of 28 patents in total, none of which have expired yet. Among these, the patent with the manufacturers' extension is set to expire last on 05 May, 2041, setting the earliest possible release date for the Opzelura generic version. Below is the detail of the patent: